Zimmer Biomet (NYSE:ZBH)‘s stock had its “buy” rating restated by equities researchers at Oppenheimer in a report released on Tuesday.

A number of other brokerages have also weighed in on ZBH. SunTrust Banks set a $136.00 target price on shares of Zimmer Biomet and gave the company a “buy” rating in a research note on Wednesday, November 1st. Royal Bank of Canada cut their target price on shares of Zimmer Biomet to $125.00 and set an “outperform” rating on the stock in a research note on Tuesday, November 7th. Morgan Stanley cut their target price on shares of Zimmer Biomet from $146.00 to $136.00 and set an “overweight” rating on the stock in a research note on Thursday, November 2nd. BMO Capital Markets cut their target price on shares of Zimmer Biomet from $140.00 to $135.00 and set an “outperform” rating on the stock in a research note on Thursday, November 2nd. Finally, Deutsche Bank raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating and set a $128.00 target price on the stock in a research note on Tuesday, November 14th. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, fifteen have given a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $135.14.

Shares of Zimmer Biomet (NYSE:ZBH) opened at $121.18 on Tuesday. The firm has a market cap of $24,540.00, a PE ratio of 14.18, a PEG ratio of 1.78 and a beta of 1.15. The company has a debt-to-equity ratio of 0.88, a quick ratio of 0.78 and a current ratio of 1.47. Zimmer Biomet has a 52 week low of $100.87 and a 52 week high of $133.49.

Zimmer Biomet (NYSE:ZBH) last announced its earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.02). The company had revenue of $1.82 billion for the quarter, compared to the consensus estimate of $1.83 billion. Zimmer Biomet had a net margin of 8.36% and a return on equity of 16.29%. The company’s revenue for the quarter was down .8% on a year-over-year basis. During the same period in the previous year, the firm posted $1.79 EPS. sell-side analysts forecast that Zimmer Biomet will post 8.03 earnings per share for the current fiscal year.

Large investors have recently bought and sold shares of the stock. BlackRock Inc. lifted its stake in shares of Zimmer Biomet by 4.1% in the second quarter. BlackRock Inc. now owns 17,419,463 shares of the medical equipment provider’s stock worth $2,236,657,000 after buying an additional 679,080 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Zimmer Biomet by 2.6% in the second quarter. Vanguard Group Inc. now owns 13,380,517 shares of the medical equipment provider’s stock worth $1,718,057,000 after buying an additional 339,106 shares in the last quarter. Longview Partners Guernsey LTD lifted its stake in shares of Zimmer Biomet by 17.7% in the third quarter. Longview Partners Guernsey LTD now owns 7,506,684 shares of the medical equipment provider’s stock worth $878,958,000 after buying an additional 1,128,973 shares in the last quarter. Nordea Investment Management AB lifted its stake in shares of Zimmer Biomet by 7.3% in the third quarter. Nordea Investment Management AB now owns 5,277,660 shares of the medical equipment provider’s stock worth $617,961,000 after buying an additional 357,302 shares in the last quarter. Finally, Jana Partners LLC lifted its stake in shares of Zimmer Biomet by 16.6% in the third quarter. Jana Partners LLC now owns 4,662,497 shares of the medical equipment provider’s stock worth $545,932,000 after buying an additional 662,497 shares in the last quarter. 85.92% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: “Oppenheimer Reiterates Buy Rating for Zimmer Biomet (ZBH)” was originally posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another website, it was stolen and republished in violation of U.S. and international copyright & trademark law. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/12/21/oppenheimer-reiterates-buy-rating-for-zimmer-biomet-zbh.html.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Analyst Recommendations for Zimmer Biomet (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.